Neuroprotective treatment methods using selective iNOS inhibitors

Details for Australian Patent Application No. 2002327042 (hide)

Owner PHARMACIA CORPORATION MANNING, Pamela, T. CONNOR, Jane, R.

Inventors Manning, Pamela, T.; Connor, Jane, R.

Agent EF WELLINGTON & CO of **** Road Southbank Melbourne VIC 3006 Australia

Pub. Number AU-A-2002327042

PCT Number PCT/US02/30214

PCT Pub. Number WO2003/026638

Priority 09/961,521 24.09.01 US

Filing date 24 September 2002

Wipo publication date 7 April 2003

International Classifications

A61K 031/155 - Amidines (), e.g. guanidine (HNC(NH)NH), isourea (HNC(OH)NH), isothiourea (HNC(SH)NH)

A61K 031/16 - Amides, e.g. hydroxamic acids

Event Publications

23 January 2003 Complete Application Filed

  Priority application(s): 09/961,521 24.09.01 US

26 June 2003 Application Open to Public Inspection

  Published as AU-A-2002327042

19 August 2004 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 19 Jul 2004

26 August 2004 Amendment Made

  The nature of the amendment is: Delete the co-applicants Connor, Jane and Manning, Pamela

23 March 2006 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002327043-IN SITU METHOD FOR DETERMINING SOIL LIQUEFACTION TENDENCY AND ITS PREVENTION BY ELECTRO-OSMOSIS

2002327041-Ophthalmologic treatment methods using selective iNOS inhibitors